Duration of triple antithrombotic therapy and clinical outcomes after percutaneous coronary intervention in atrial fibrillation.
Mark A SammutDwayne ConwayJavaid IqbalArvindra KrishnamurthyKenneth P MorganPaul D MorrisJames D RichardsonAlexander M K RothmanJulian P GunnRobert F StoreyPublished in: Expert review of cardiovascular therapy (2024)
TAT post-PCI for ≤1 week was associated with less bleeding despite greater use of ticagrelor/prasugrel but similar MACCE versus 1-month TAT. These findings support further studies on safety and efficacy of dual therapy with ticagrelor/prasugrel immediately after PCI.
Keyphrases
- percutaneous coronary intervention
- atrial fibrillation
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- acute coronary syndrome
- antiplatelet therapy
- acute myocardial infarction
- coronary artery disease
- coronary artery bypass grafting
- oral anticoagulants
- left atrial
- catheter ablation
- left atrial appendage
- coronary artery bypass
- direct oral anticoagulants
- heart failure
- clinical trial
- randomized controlled trial
- mesenchymal stem cells
- stem cells
- mitral valve
- venous thromboembolism
- replacement therapy
- left ventricular